𝐌𝐞𝐝𝐭𝐫𝐨𝐧𝐢𝐜’𝐬 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 (𝐏𝐚𝐫𝐭 𝐈): 𝐖𝐨𝐫𝐤𝐟𝐨𝐫𝐜𝐞 𝐄𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧

While headcount may not be a standard metric for evaluating company performance, it can reflect the scale and growth of a business, as it is closely tied to company economics. This is mainly because employee-related costs, including compensation, benefits, training, and workspace expenses, often represent one of the most significant components of a company’s operating expenses.

Historically, Medtronic pursued growth in its core markets, namely Cardiovascular, Restorative Therapies, and Diabetes. The development was achieved both organically and through a series of small and strategic tuck-in acquisitions that complemented the company’s existing offerings. This is reflected in Medtronic’s steady headcount growth over the years until 2015.

The 2015 acquisition of Covidien for $43B marked a significant departure from Medtronic’s historical approach. At the time, Medtronic employed approximately 50,000 people, while Covidien (Medtronic Minimally Invasive Therapies Group) brought an additional 40,000 employees, making the acquisition more like a merger. Covidien also offered very different products, which led to the creation of a new product category for Medtronic named Minimally Invasive Therapies.

This major expansion introduced substantial organizational, cultural, financial, and operational complexities for Medtronic, which directly impacted its economics. The merger effectively brought two headquarters together, resulting in duplications of numerous roles and responsibilities, which in some cases led to layoffs and early retirements of multiple senior executives.

In the years following the largest MedTech acquisition, Medtronic continued to focus on integrating Covidien, divesting its low-margin businesses, and restoring its financial health. This is also reflected in Medtronic’s workforce, which has remained essentially unchanged since the acquisition.

To break the pattern, the company has recently announced its plan to spin off its diabetes business. The move has raised concerns, but the hope is that it will help Medtronic regain its growth trajectory.

I will explore the evolution of Medtronic’s economic output and operational efficiency in more detail in Parts II and III.